Home/Pipeline/TerXT

TerXT

Schizophrenia

Late-stage (Pre-Phase 3)Active

Key Facts

Indication

Schizophrenia

Phase

Late-stage (Pre-Phase 3)

Status

Active

Company

Terran Biosciences

About Terran Biosciences

Terran Biosciences is a private, platform-based biotechnology company pioneering a multi-faceted approach to neuroscience. Its strategy integrates late-stage clinical assets, a broad psychedelic and empathogen development program, advanced drug design capabilities, and a commercial AI software platform for neuroimaging. With a pipeline featuring several late-stage programs for schizophrenia and Alzheimer's disease, and key partnerships with Sanofi and Pierre Fabre, Terran is positioned to address significant unmet needs in psychiatry and neurology. The company operates as a pre-revenue entity, advancing its diverse portfolio through strategic licensing, internal R&D, and its first FDA-cleared software product.

View full company profile

Therapeutic Areas

Neurological Diseases Psychiatric Diseases Schizophrenia Alzheimer's Disease Parkinson's Disease Psychosis

Other Schizophrenia Drugs

Drug	Company	Phase	Status
DB103 (Pomaglumetad)	Denovo Biopharma	Phase 2b/3	Active
ZZ6398	Zhongze Therapeutics	Phase 1/2	Active
RBP-7000 (PERSERIS®)	Indivior	Marketed	Commercial
Undisclosed Programs	johnson-and-johnson-innovative-medicine	Pipeline	Active
Schizophrenia Candidate	Teva	Phase 3	Active
Schizophrenia Model Service	NeuroProof	Pre-clinical	Active
LYN-005 (Nortiva)	Lyndra	Phase 3	Active
Undisclosed Program	Curemark	Preclinical	Active
Schizophrenia Intermediate	OFD Biopharma	Proof of concept	Active
Schizophrenia	Keltic Pharma Therapeutics	Pre-clinical	Active
AVAT-031	Avata Biosciences	Discovery	Active
Risperidone Implant	Delpor	Phase 1b/2a / Late-stage	Active